Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893723 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL3504659 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21454626 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL454245 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL321552 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL336249 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL17512849 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21320722 | 0.97 | HSD17B10 (0.54) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL1661688 | 0.97 | — | — | |
| SCHEMBL661575 | 0.97 | HSD17B10 (0.58) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1729795-B1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES INC (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2474318-A1 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8071539-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7977306-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110009312-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7569384-B2 | With improved shelf life and storage stability; expression vectors and host cells; therapeutic proteins are chemically or genetically fused to albumin; hypoglycemic agents, analgesics; retinopathy, cardiovascular disease, obesity, renal disease, neuropathy | HUMAN GENOME SCIENCES, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080293629-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20070259815-A1 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1708751-A4 | METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS | VACCINEX INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070027306-A1 | With improved shelf life and storage stability; expression vectors and host cells; therapeutic proteins are chemically or genetically fused to albumin; hypoglycemic agents, analgesics; retinopathy, cardiovascular disease, obesity, renal disease, neuropathy | HUMAN GENOME SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1534336-A4 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS | HUMAN GENOME SCIENCES INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1594530-A2 | ALBUMIN FUSION PROTEINS | Human Genome Sciences, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1463752-A4 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES INC (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005055936-A2 | METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS | VACCINEX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1534336-A2 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS | Human Genome Sciences, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005003296-A2 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1463752-A2 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004058309-A1 | NEUTROKINE-ALPHA CONJUGATE, NEUTROKINE-ALPHA COMPLEX, AND USES THEREOF | HUMAN GENOME SCIENCES, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004016753-A2 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS | HUMAN GENOME SCIENCES, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003059934-A2 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293629-A1 | Albumin Fusion Proteins | ALB, FABP1, IAPP | HSD17B10 3267/4885GAA 351/4885ALDH1A1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.